We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 355

Supplemental briefs filed in stem cell funding dispute
  • Shook Hardy & Bacon LLP
  • USA
  • July 14 2011

The parties to a dispute over whether National Institutes of Health (NIH) guidelines on stem cell research violate a congressional appropriations rider that bars federal funding for research in which a human embryo is destroyed have filed their supplemental briefs on competing motions for summary judgment pending before a U.S. district court in Washington, D.C


Lab Trade Association presses FDA on plan to regulate laboratory developed tests
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

The American Clinical Laboratory Association (ACLA) has submitted a citizen petition to the Food and Drug Administration (FDA), asking the agency to


Neumedicines receives $8.3 million from BARDA for radiation sickness drug
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Pasadena-based Neumedicines Inc. has reportedly received $8.3 million from the Biomedical Advanced Research & Development Authority (BARDA) of the U


SCOTUS refuses to hear challenge to government stem cell research funding
  • Shook Hardy & Bacon LLP
  • USA
  • January 10 2013

The U.S. Supreme Court (SCOTUS) has rejected a request that it review a D.C. Circuit Court of Appeals ruling dismissing a challenge to government funding


States consider bills to allow biosimilar substitution for brand-name biologics
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

In the absence of U.S. Food and Drug Administration (FDA) rules providing a pathway of approval for biosimilar drugs, legislators in several states


Biotech investments rise in Q4 2012, but remain off for the year
  • Shook Hardy & Bacon LLP
  • USA
  • January 24 2013

Pricewatershouse Coopers LLP has released its fourth quarter (Q4) and final 2012 venture capital investment reports and notes that "Biotechnology


SCOTUS sides with FTC in reverse payment deals
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

A divided U.S. Supreme Court has determined that patent-infringement settlement agreements requiring the patentee to pay the claimed infringer


Biotech set to raise $86 million in IPO to support cancer and IEM products
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

Agios Pharmaceuticals, Inc. has filed a registration statement with the U.S. Securities and Exchange Commission indicating its intent to raise up to


Biopharmaceutical companies have 215 heart diseasestroke drugs in R&D pipeline
  • Shook Hardy & Bacon LLP
  • USA
  • June 20 2013

According to a new Pharmaceutical Research and Manufacturers of America (PhRMA) report, U.S. biopharmaceutical companies have 215 medicines under


Congress advances pharma supply chain and animal-drug user-fee laws
  • Shook Hardy & Bacon LLP
  • USA
  • May 16 2013

The House Energy and Commerce Subcommittee on Health has reportedly approved draft legislation that would change the existing lot-level